HEPA

Hepion Pharmaceuticals, Inc. (HEPA) | Rumor.io

Hepion Pharmaceuticals

HEPA

Attention (50-day avg)0%

Attention rank (50-day avg)#4,760

Bullish sentiment (50-day avg)0%

Price to earnings ratio0.06

Market capitalization5.8M

Earnings per share-0.03

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-8.3M

Social

What share of all stock conversation is about HEPA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% -0.01

Nov 24

$HEPA mentioned as the start of a new development or opportunity.
No additional information or context is provided about the nature of this development.
The tone of the post is informal and playful.

Generated by AI

Sentiment

Of the messages about HEPA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	24.14% -48.83
Bearish	—	—	—	75.86% +48.83

Bullish· May 7

$HEPA is expected to open above $0.6 tomorrow and potentially surpass $1 by the end of the day.
The company has entered into a Letter of Intent (LOI) for a partnership to launch multiple new products, moving towards commercialization and its first revenues.
The stock's recent run suggests that it is in the right hands, with a setup that could lead to significant gains.

Bearish· May 7

$HEPA is expected to drop to $1.40, with sellers regretting their decisions.
The company's management, led by Brancaccio, has made several questionable decisions, including stopping a trial without shareholder notice, engaging in a reverse merger, and conducting a cashless offering that gave away company value.
Over 50% of the float is short, and the market is expected to see a significant squeeze, potentially leading to a drop in the stock price below $0.30.

Generated by AI

Topics

Of the messages about HEPA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	93.02%
Analysts	—	—	0%	0%
Controversies	—	—	0%	6.98%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	0%

Announcements· May 7

Hepion Pharmaceuticals, Inc. ($HEPA) has executed a binding letter of intent with New Day Diagnostics to commercialize diagnostic tests for Celiac Disease, Respiratory Multiplex, H. Pylori, and HCC.
The partnership aims to launch multiple new products, marking the company's first revenue-generating endeavors.
The complete float of $HEPA shares (11.0M) has been traded, with the traded volume currently at 11.0M shares.

Controversies· Nov 18

A potential pairs trading scheme involving HEPA and TLSA stocks has been reported, with the scheme allegedly being run by Cerrone and/or his Tiziana guys who also serve on the Hepion Board of Directors.
The scheme's purpose is to use the Tiziana stock to hold back the Hepion stock, with the odds of it not being them being "pretty close to incalculable" given the ties between Tiziana and Hepion.
A package has been submitted to the SEC for investigation, and they have it now.

Technical Analysis· Jan 23

$HEPA has a calculated climb to an afternoon run, with a potential target of $0.21.
The stock has formed a bullish pennant and is about to start ripping out of a bull flag, with a high of $0.321 and a current price of $0.1875.
$HEPA has a 14-day win streak and is on a choppy uptrend, with a 90-day low of $0.1025 and a 1.70s target on the 4-hour chart.

Generated by AI

Community

Of the messages about HEPA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	100%	73.19%
Newcomers	—	—	0%	26.81%

Regulars· Jan 28

$HEPA is up 12.03% in the last 20 minutes, with a new high of the day being pushed.
Regulars are expecting a breakout at $0.2340, with some speculating about a potential reclaim of the VWAP.
The asset is experiencing heavy trading volume, with 57M shares traded in the last 20 minutes, exceeding the float of 5.3M shares.

Newcomers· Jun 16

Many newcomers are focusing on Hepion Pharmaceuticals' (HEPA) valuation, with some noting its share structure has been updated.
New investors are discussing Hepion Pharmaceuticals' (HEPA) dollar volume, which has exceeded $10,000.
Some newcomers are considering Hepion Pharmaceuticals (HEPA) as an advancer in the OTC market, based on its percentage change.

Generated by AI

News

Hepion Pharmaceuticals appoints new auditor, dismisses Grassi & Co.

2d agoInvesting.com

Wednesday’s insider buys and sells: Hepion insiders invest $800K By Investing.com

1mo agoInvesting.com

Also Discussed

Investors talking about HEPA also mention

#	Name	Attention
1	Enveric Biosciences Inc.ENVB	0%0
2	Viveve Medical Inc.VIVE	0%0
3	ASLN - ASLAN Pharmaceuticals Limited	——
4	Legacy Education Inc.LGCY	0%new
5	Daré Bioscience, Inc.DARE	0%0
6	OBLN - Obalon Therapeutics, Inc.	——
7	Eltek Ltd.ELTK	0%new
8	Moleculin Biotech, Inc.MBRX	0%0
9	BIMI - BIMI International Medical Inc.	——
10	Protara Therapeutics, Inc.TARA	0%0

Hepion Pharmaceuticals, Inc.

Healthcare
Biotechnology

Hepion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in the development of therapies for chronic liver diseases. Its key asset, Rencofilstat, is a potent cyclophilin inhibitor aimed at treating conditions such as non-alcoholic steatohepatitis (NASH), liver fibrosis, and hepatocellular carcinoma (HCC). Rencofilstat targets multiple molecular pathways involved in liver disease progression, from initial triggers to those impairing liver function. The company leverages its AI-POWR platform for integrative bioinformatic analysis, utilizing both proprietary clinical data and public multi-omic databases to inform drug development. Recently, Hepion has transitioned towards developing and licensing diagnostic tests for diseases including celiac disease, respiratory infections, Helicobacter pylori, and HCC. Incorporated in 2013 and headquartered in Morristown, New Jersey, Hepion holds FDA Fast Track and Orphan Drug designations for Rencofilstat, reflecting its significance in addressing unmet medical needs in liver disease therapeutics.

Website

Location

55 Madison Avenue

Morristown, NJ, 07960

United States

Social

What share of all stock conversation is about HEPA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% -0.01

Nov 24

$HEPA mentioned as the start of a new development or opportunity.
No additional information or context is provided about the nature of this development.
The tone of the post is informal and playful.

Generated by AI

Sentiment

Of the messages about HEPA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	24.14% -48.83
Bearish	—	—	—	75.86% +48.83

Bullish· May 7

$HEPA is expected to open above $0.6 tomorrow and potentially surpass $1 by the end of the day.
The company has entered into a Letter of Intent (LOI) for a partnership to launch multiple new products, moving towards commercialization and its first revenues.
The stock's recent run suggests that it is in the right hands, with a setup that could lead to significant gains.

Bearish· May 7

$HEPA is expected to drop to $1.40, with sellers regretting their decisions.
The company's management, led by Brancaccio, has made several questionable decisions, including stopping a trial without shareholder notice, engaging in a reverse merger, and conducting a cashless offering that gave away company value.
Over 50% of the float is short, and the market is expected to see a significant squeeze, potentially leading to a drop in the stock price below $0.30.

Generated by AI

Topics

Of the messages about HEPA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	93.02%
Analysts	—	—	0%	0%
Controversies	—	—	0%	6.98%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	0%

Announcements· May 7

Hepion Pharmaceuticals, Inc. ($HEPA) has executed a binding letter of intent with New Day Diagnostics to commercialize diagnostic tests for Celiac Disease, Respiratory Multiplex, H. Pylori, and HCC.
The partnership aims to launch multiple new products, marking the company's first revenue-generating endeavors.
The complete float of $HEPA shares (11.0M) has been traded, with the traded volume currently at 11.0M shares.

Controversies· Nov 18

A potential pairs trading scheme involving HEPA and TLSA stocks has been reported, with the scheme allegedly being run by Cerrone and/or his Tiziana guys who also serve on the Hepion Board of Directors.
The scheme's purpose is to use the Tiziana stock to hold back the Hepion stock, with the odds of it not being them being "pretty close to incalculable" given the ties between Tiziana and Hepion.
A package has been submitted to the SEC for investigation, and they have it now.

Technical Analysis· Jan 23

$HEPA has a calculated climb to an afternoon run, with a potential target of $0.21.
The stock has formed a bullish pennant and is about to start ripping out of a bull flag, with a high of $0.321 and a current price of $0.1875.
$HEPA has a 14-day win streak and is on a choppy uptrend, with a 90-day low of $0.1025 and a 1.70s target on the 4-hour chart.

Generated by AI

Community

Of the messages about HEPA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	100%	73.19%
Newcomers	—	—	0%	26.81%

Regulars· Jan 28

$HEPA is up 12.03% in the last 20 minutes, with a new high of the day being pushed.
Regulars are expecting a breakout at $0.2340, with some speculating about a potential reclaim of the VWAP.
The asset is experiencing heavy trading volume, with 57M shares traded in the last 20 minutes, exceeding the float of 5.3M shares.

Newcomers· Jun 16

Many newcomers are focusing on Hepion Pharmaceuticals' (HEPA) valuation, with some noting its share structure has been updated.
New investors are discussing Hepion Pharmaceuticals' (HEPA) dollar volume, which has exceeded $10,000.
Some newcomers are considering Hepion Pharmaceuticals (HEPA) as an advancer in the OTC market, based on its percentage change.

Generated by AI

Hepion Pharmaceuticals

Social

Nov 24

Bullish· May 7

Bearish· May 7

Announcements· May 7

Controversies· Nov 18

Technical Analysis· Jan 23

Regulars· Jan 28

Newcomers· Jun 16

Hepion Pharmaceuticals appoints new auditor, dismisses Grassi & Co.

Wednesday’s insider buys and sells: Hepion insiders invest $800K By Investing.com

Hepion Pharmaceuticals director Stetz buys $25,000 in common stock

Hepion Pharmaceuticals interim CEO Gary Stetz buys $100,000 in stock

Hepion Pharmaceuticals director Michael Purcell buys $100,000 in stock

Hepion Pharmaceuticals executive chairman LoPriore buys $500,000 in stock

Also Discussed

Hepion Pharmaceuticals, Inc.

Company Information

Location

Hepion Pharmaceuticals appoints new auditor, dismisses Grassi & Co.

Wednesday’s insider buys and sells: Hepion insiders invest $800K By Investing.com

Hepion Pharmaceuticals director Stetz buys $25,000 in common stock

Hepion Pharmaceuticals interim CEO Gary Stetz buys $100,000 in stock

Hepion Pharmaceuticals director Michael Purcell buys $100,000 in stock

Hepion Pharmaceuticals executive chairman LoPriore buys $500,000 in stock

Also Discussed

Social

Nov 24

Bullish· May 7

Bearish· May 7

Announcements· May 7

Controversies· Nov 18

Technical Analysis· Jan 23

Regulars· Jan 28

Newcomers· Jun 16